#begin document (en_3772.txt); part 000
en_3772.txt	0	0	Depression	NN	(TOP(S(NP*)	-	-	-	-	*	-
en_3772.txt	0	1	'	:	*	-	-	-	-	*	-
en_3772.txt	0	2	s	VBZ	(VP*	-	-	-	-	*	-
en_3772.txt	0	3	Psychedelic	NNP	(NP*	-	-	-	-	*	-
en_3772.txt	0	4	Solution	NNP	*))	-	-	-	-	*	-
en_3772.txt	0	5	?	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	ZURICH	SYM	(TOP(S(X*)	-	-	-	-	*	-
en_3772.txt	0	1	–	SYM	(X(X*)	-	-	-	-	*	-
en_3772.txt	0	2	According	VBG	(PP*	-	-	-	-	*	-
en_3772.txt	0	3	to	TO	(PP*	-	-	-	-	*	-
en_3772.txt	0	4	the	DT	(NP*	-	-	-	-	*	-
en_3772.txt	0	5	World	NNP	*	-	-	-	-	*	-
en_3772.txt	0	6	Health	NNP	*	-	-	-	-	*	-
en_3772.txt	0	7	Organization	NNP	*))))	-	-	-	-	*	-
en_3772.txt	0	8	,	,	*	-	-	-	-	*	-
en_3772.txt	0	9	depression	NN	(NP*)	-	-	-	-	*	(0)
en_3772.txt	0	10	affects	VBZ	(VP*	-	-	-	-	*	-
en_3772.txt	0	11	an	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	12	estimated	VBN	*	-	-	-	-	*	-
en_3772.txt	0	13	350	CD	(QP*	-	-	-	-	*	-
en_3772.txt	0	14	million	CD	*)	-	-	-	-	*	-
en_3772.txt	0	15	people	NNS	*)	-	-	-	-	*	-
en_3772.txt	0	16	worldwide	JJ	(ADJP*))	-	-	-	-	*	-
en_3772.txt	0	17	,	,	*	-	-	-	-	*	-
en_3772.txt	0	18	making	VBG	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	19	it	PRP	(S(NP*)	-	-	-	-	*	(0)
en_3772.txt	0	20	one	CD	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	21	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	22	the	DT	(NP*	-	-	-	-	*	-
en_3772.txt	0	23	most	RBS	(ADJP*	-	-	-	-	*	-
en_3772.txt	0	24	prevalent	JJ	*)	-	-	-	-	*	-
en_3772.txt	0	25	psychiatric	JJ	*	-	-	-	-	*	-
en_3772.txt	0	26	conditions	NNS	*)))))))	-	-	-	-	*	-
en_3772.txt	0	27	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	But	CC	(TOP(S*	-	-	-	-	*	-
en_3772.txt	0	1	only	RB	(S(NP(NP(QP*	-	-	-	-	*	-
en_3772.txt	0	2	about	IN	*	-	-	-	-	*	-
en_3772.txt	0	3	half	NN	*))	-	-	-	-	*	-
en_3772.txt	0	4	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	5	those	DT	(NP(NP*)	-	-	-	-	*	(1
en_3772.txt	0	6	who	WP	(SBAR(WHNP*)	-	-	-	-	*	-
en_3772.txt	0	7	try	VBP	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	8	antidepressant	JJ	(NP*	-	-	-	-	*	-
en_3772.txt	0	9	drugs	NNS	*)))))))	-	-	-	-	*	1)
en_3772.txt	0	10	respond	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	11	to	TO	(PP*	-	-	-	-	*	-
en_3772.txt	0	12	them	PRP	(NP*))))	-	-	-	-	*	(1)
en_3772.txt	0	13	,	,	*	-	-	-	-	*	-
en_3772.txt	0	14	and	CC	*	-	-	-	-	*	-
en_3772.txt	0	15	those	DT	(S(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	16	who	WP	(SBAR(WHNP*)	-	-	-	-	*	-
en_3772.txt	0	17	do	VBP	(S(VP*))))	-	-	-	-	*	-
en_3772.txt	0	18	may	MD	(VP*	-	-	-	-	*	-
en_3772.txt	0	19	have	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	20	to	TO	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	21	wait	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	22	several	JJ	(UCP(NP*	-	-	-	-	*	-
en_3772.txt	0	23	weeks	NNS	*)	-	-	-	-	*	-
en_3772.txt	0	24	or	CC	*	-	-	-	-	*	-
en_3772.txt	0	25	even	RB	(PP(NP*	-	-	-	-	*	-
en_3772.txt	0	26	months	NNS	*)	-	-	-	-	*	-
en_3772.txt	0	27	before	IN	*	-	-	-	-	*	-
en_3772.txt	0	28	experiencing	VBG	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	29	relief	NN	(NP*)	-	-	-	-	*	-
en_3772.txt	0	30	–	SYM	(X(X*)	-	-	-	-	*	-
en_3772.txt	0	31	a	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	32	critical	JJ	*	-	-	-	-	*	-
en_3772.txt	0	33	failing	NN	*)	-	-	-	-	*	-
en_3772.txt	0	34	for	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	35	people	NNS	(NP*))))	-	-	-	-	*	-
en_3772.txt	0	36	at	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	37	immediate	JJ	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	38	risk	NN	*)	-	-	-	-	*	-
en_3772.txt	0	39	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	40	suicide	NN	(NP*))))))))))))))	-	-	-	-	*	-
en_3772.txt	0	41	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	Fast-acting	JJ	(TOP(S(NP*	-	-	-	-	*	-
en_3772.txt	0	1	antidepressants	NNS	*)	-	-	-	-	*	-
en_3772.txt	0	2	are	VBP	(VP*	-	-	-	-	*	-
en_3772.txt	0	3	thus	RB	(ADVP*)	-	-	-	-	*	-
en_3772.txt	0	4	urgently	RB	(VP(ADVP*)	-	-	-	-	*	-
en_3772.txt	0	5	needed	VBN	*))	-	-	-	-	*	-
en_3772.txt	0	6	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	Ketamine	NNP	(TOP(S(S(NP*)	-	-	-	-	*	-
en_3772.txt	0	1	–	SYM	(VP*	-	-	-	-	*	-
en_3772.txt	0	2	a	DT	(NP(NP*	-	-	-	-	*	(2
en_3772.txt	0	3	drug	NN	*)	-	-	-	-	*	-
en_3772.txt	0	4	primarily	RB	(VP(ADVP*)	-	-	-	-	*	-
en_3772.txt	0	5	used	VBN	*	-	-	-	-	*	-
en_3772.txt	0	6	as	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	7	an	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	8	anesthetic	NN	*)	-	-	-	-	*	-
en_3772.txt	0	9	in	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	10	veterinary	JJ	(NP*	-	-	-	-	*	-
en_3772.txt	0	11	medicine	NN	*))))))))	-	-	-	-	*	2)
en_3772.txt	0	12	and	CC	*	-	-	-	-	*	-
en_3772.txt	0	13	as	IN	(S(PP*	-	-	-	-	*	-
en_3772.txt	0	14	a	DT	(NP(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	15	short-term	JJ	*	-	-	-	-	*	-
en_3772.txt	0	16	anesthetic	NN	*)	-	-	-	-	*	-
en_3772.txt	0	17	and	CC	*	-	-	-	-	*	-
en_3772.txt	0	18	analgesic	JJ	*)	-	-	-	-	*	-
en_3772.txt	0	19	in	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	20	hospitals	NNS	(NP*))	-	-	-	-	*	-
en_3772.txt	0	21	during	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	22	surgery	NN	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	23	or	CC	*	-	-	-	-	*	-
en_3772.txt	0	24	other	JJ	(NP*	-	-	-	-	*	-
en_3772.txt	0	25	painful	JJ	*	-	-	-	-	*	-
en_3772.txt	0	26	procedures	NNS	*)))))	-	-	-	-	*	-
en_3772.txt	0	27	–	SYM	(NP*)	-	-	-	-	*	-
en_3772.txt	0	28	is	VBZ	(VP*	-	-	-	-	*	-
en_3772.txt	0	29	currently	RB	(ADVP*)	-	-	-	-	*	-
en_3772.txt	0	30	the	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	31	rising	VBG	*	-	-	-	-	*	-
en_3772.txt	0	32	star	NN	*)	-	-	-	-	*	-
en_3772.txt	0	33	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	34	depression	NN	(NP*	-	-	-	-	*	-
en_3772.txt	0	35	research	NN	*)))))	-	-	-	-	*	-
en_3772.txt	0	36	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	It	PRP	(TOP(S(NP*)	-	-	-	-	*	-
en_3772.txt	0	1	appears	VBZ	(VP*	-	-	-	-	*	-
en_3772.txt	0	2	to	TO	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	3	ease	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	4	depression	NNS	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	5	'	POS	*)	-	-	-	-	*	-
en_3772.txt	0	6	s	JJ	*	-	-	-	-	*	-
en_3772.txt	0	7	most	RBS	(ADJP*	-	-	-	-	*	-
en_3772.txt	0	8	severe	JJ	*)	-	-	-	-	*	-
en_3772.txt	0	9	symptoms	NNS	*)	-	-	-	-	*	-
en_3772.txt	0	10	within	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	11	minutes	NNS	(NP*	-	-	-	-	*	-
en_3772.txt	0	12	or	CC	*	-	-	-	-	*	-
en_3772.txt	0	13	hours	NNS	*)))))	-	-	-	-	*	-
en_3772.txt	0	14	,	,	*	-	-	-	-	*	-
en_3772.txt	0	15	even	RB	(PP(ADVP*)	-	-	-	-	*	-
en_3772.txt	0	16	in	IN	*	-	-	-	-	*	-
en_3772.txt	0	17	patients	NNS	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	18	who	WP	(SBAR(WHNP*)	-	-	-	-	*	-
en_3772.txt	0	19	have	VBP	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	20	a	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	21	dismal	JJ	*	-	-	-	-	*	-
en_3772.txt	0	22	track	NN	*	-	-	-	-	*	-
en_3772.txt	0	23	record	NN	*)	-	-	-	-	*	-
en_3772.txt	0	24	with	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	25	other	JJ	(NP*	-	-	-	-	*	-
en_3772.txt	0	26	treatments	NNS	*)))))))))	-	-	-	-	*	-
en_3772.txt	0	27	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	In	IN	(TOP(S(S(PP*	-	-	-	-	*	-
en_3772.txt	0	1	the	DT	(NP*	-	-	-	-	*	-
en_3772.txt	0	2	first	JJ	*	-	-	-	-	*	-
en_3772.txt	0	3	controlled	VBN	*	-	-	-	-	*	-
en_3772.txt	0	4	study	NN	*))	-	-	-	-	*	-
en_3772.txt	0	5	,	,	*	-	-	-	-	*	-
en_3772.txt	0	6	researchers	NNS	(NP*)	-	-	-	-	*	-
en_3772.txt	0	7	reported	VBD	(VP*	-	-	-	-	*	-
en_3772.txt	0	8	a	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	9	50	CD	(ADJP*	-	-	-	-	*	-
en_3772.txt	0	10	%	NN	*)	-	-	-	-	*	-
en_3772.txt	0	11	decline	NN	*)	-	-	-	-	*	-
en_3772.txt	0	12	in	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	13	symptoms	NNS	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	14	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	15	depression	NN	(NP*))))	-	-	-	-	*	-
en_3772.txt	0	16	within	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	17	two	CD	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	18	hours	NNS	*)	-	-	-	-	*	-
en_3772.txt	0	19	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	20	a	DT	(NP*	-	-	-	-	*	-
en_3772.txt	0	21	ketamine	JJ	*	-	-	-	-	*	-
en_3772.txt	0	22	infusion	NN	*)))))))	-	-	-	-	*	-
en_3772.txt	0	23	,	,	*	-	-	-	-	*	-
en_3772.txt	0	24	and	CC	*	-	-	-	-	*	-
en_3772.txt	0	25	one-third	JJ	(S(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	26	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	27	patients	NNS	(NP*)))	-	-	-	-	*	-
en_3772.txt	0	28	were	VBD	(VP*	-	-	-	-	*	-
en_3772.txt	0	29	virtually	RB	(ADJP*	-	-	-	-	*	-
en_3772.txt	0	30	symptom-free	JJ	*	-	-	-	-	*	-
en_3772.txt	0	31	within	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	32	a	DT	(NP*	-	-	-	-	*	-
en_3772.txt	0	33	day	NN	*)))))	-	-	-	-	*	-
en_3772.txt	0	34	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	Moreover	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_3772.txt	0	1	,	,	*	-	-	-	-	*	-
en_3772.txt	0	2	patients	NNS	(NP*)	-	-	-	-	*	-
en_3772.txt	0	3	reported	VBD	(VP*	-	-	-	-	*	-
en_3772.txt	0	4	diminished	JJ	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	5	thoughts	NNS	*)	-	-	-	-	*	-
en_3772.txt	0	6	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	7	suicide	NN	(NP*)))	-	-	-	-	*	-
en_3772.txt	0	8	a	DT	(PP(NP*	-	-	-	-	*	-
en_3772.txt	0	9	mere	JJ	*	-	-	-	-	*	-
en_3772.txt	0	10	40	CD	*	-	-	-	-	*	-
en_3772.txt	0	11	minutes	NNS	*)	-	-	-	-	*	-
en_3772.txt	0	12	after	IN	*	-	-	-	-	*	-
en_3772.txt	0	13	receiving	VBG	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	14	an	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	15	intravenous	JJ	*	-	-	-	-	*	-
en_3772.txt	0	16	infusion	NN	*)	-	-	-	-	*	-
en_3772.txt	0	17	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	18	the	DT	(NP*	-	-	-	-	*	(2
en_3772.txt	0	19	drug	NN	*)))))))	-	-	-	-	*	2)
en_3772.txt	0	20	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	In	IN	(TOP(S(PP*	-	-	-	-	*	-
en_3772.txt	0	1	some	DT	(NP*	-	-	-	-	*	-
en_3772.txt	0	2	patients	NNS	*))	-	-	-	-	*	-
en_3772.txt	0	3	,	,	*	-	-	-	-	*	-
en_3772.txt	0	4	the	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	5	effects	NNS	*)	-	-	-	-	*	-
en_3772.txt	0	6	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	7	a	DT	(NP*	-	-	-	-	*	-
en_3772.txt	0	8	single	JJ	*	-	-	-	-	*	-
en_3772.txt	0	9	dose	NN	*)))	-	-	-	-	*	-
en_3772.txt	0	10	can	MD	(VP*	-	-	-	-	*	-
en_3772.txt	0	11	last	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	12	more	JJR	(NP(QP*	-	-	-	-	*	-
en_3772.txt	0	13	than	IN	*	-	-	-	-	*	-
en_3772.txt	0	14	a	DT	*)	-	-	-	-	*	-
en_3772.txt	0	15	week	NN	*)))	-	-	-	-	*	-
en_3772.txt	0	16	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	Clinicians	NNS	(TOP(S(NP*)	-	-	-	-	*	-
en_3772.txt	0	1	are	VBP	(VP*	-	-	-	-	*	-
en_3772.txt	0	2	not	RB	*	-	-	-	-	*	-
en_3772.txt	0	3	alone	JJ	(ADJP*	-	-	-	-	*	-
en_3772.txt	0	4	in	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	5	studying	VBG	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	6	ketamine	NNS	(NP(NP*	-	-	-	-	*	(3
en_3772.txt	0	7	'	POS	*)	-	-	-	-	*	-
en_3772.txt	0	8	s	JJ	*	-	-	-	-	*	-
en_3772.txt	0	9	potential	NN	*))))))	-	-	-	-	*	3)
en_3772.txt	0	10	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	Neuroscientists	NNS	(TOP(S(NP*)	-	-	-	-	*	-
en_3772.txt	0	1	have	VBP	(VP*	-	-	-	-	*	-
en_3772.txt	0	2	hailed	VBN	(VP*	-	-	-	-	*	-
en_3772.txt	0	3	it	PRP	(NP*)	-	-	-	-	*	(3)
en_3772.txt	0	4	as	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	5	the	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	6	first	JJ	*	-	-	-	-	*	-
en_3772.txt	0	7	breakthrough	NN	*)	-	-	-	-	*	-
en_3772.txt	0	8	in	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	9	depression-drug	JJ	(NP*	-	-	-	-	*	-
en_3772.txt	0	10	research	NN	*))	-	-	-	-	*	-
en_3772.txt	0	11	in	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	12	50	CD	(NP*	-	-	-	-	*	-
en_3772.txt	0	13	years	NNS	*))))))	-	-	-	-	*	-
en_3772.txt	0	14	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	Unlike	IN	(TOP(S(PP*	-	-	-	-	*	-
en_3772.txt	0	1	conventional	JJ	(NP*	-	-	-	-	*	-
en_3772.txt	0	2	antidepressants	NNS	*))	-	-	-	-	*	-
en_3772.txt	0	3	–	SYM	(NP(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	4	which	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_3772.txt	0	5	are	VBP	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	6	used	VBN	(VP*	-	-	-	-	*	-
en_3772.txt	0	7	to	TO	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	8	elevate	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	9	concentrations	NNS	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	10	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	11	the	DT	(NP*	-	-	-	-	*	-
en_3772.txt	0	12	neurotransmitters	NNS	*	-	-	-	-	*	-
en_3772.txt	0	13	serotonin	NN	*)))))))))))	-	-	-	-	*	-
en_3772.txt	0	14	,	,	*	-	-	-	-	*	-
en_3772.txt	0	15	dopamine	NN	(NP*)	-	-	-	-	*	-
en_3772.txt	0	16	,	,	*	-	-	-	-	*	-
en_3772.txt	0	17	or	CC	*	-	-	-	-	*	-
en_3772.txt	0	18	noradrenaline	NN	(NP*	-	-	-	-	*	-
en_3772.txt	0	19	–	NN	*	-	-	-	-	*	-
en_3772.txt	0	20	ketamine	NN	*))	-	-	-	-	*	-
en_3772.txt	0	21	influences	VBZ	(VP*	-	-	-	-	*	-
en_3772.txt	0	22	the	DT	(NP*	-	-	-	-	*	(4
en_3772.txt	0	23	glutamate	NN	*	-	-	-	-	*	-
en_3772.txt	0	24	system	NN	*))	-	-	-	-	*	4)
en_3772.txt	0	25	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	Glutamate	NNP	(TOP(S(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	1	,	,	*	-	-	-	-	*	-
en_3772.txt	0	2	the	DT	(NP*	-	-	-	-	*	-
en_3772.txt	0	3	major	JJ	*	-	-	-	-	*	-
en_3772.txt	0	4	excitatory	NN	*	-	-	-	-	*	-
en_3772.txt	0	5	neurotransmitter	NN	*)	-	-	-	-	*	-
en_3772.txt	0	6	,	,	*)	-	-	-	-	*	-
en_3772.txt	0	7	plays	VBZ	(VP*	-	-	-	-	*	-
en_3772.txt	0	8	a	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	9	central	JJ	*	-	-	-	-	*	-
en_3772.txt	0	10	role	NN	*)	-	-	-	-	*	-
en_3772.txt	0	11	in	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	12	mediating	VBG	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	13	nearly	RB	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	14	all	DT	*	-	-	-	-	*	-
en_3772.txt	0	15	forms	NNS	*)	-	-	-	-	*	-
en_3772.txt	0	16	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	17	brain	NN	(NP*	-	-	-	-	*	-
en_3772.txt	0	18	function	NN	*))	-	-	-	-	*	-
en_3772.txt	0	19	,	,	*	-	-	-	-	*	-
en_3772.txt	0	20	including	VBG	(PP*	-	-	-	-	*	-
en_3772.txt	0	21	learning	NN	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	22	,	,	*	-	-	-	-	*	-
en_3772.txt	0	23	memory	NN	(NP*)	-	-	-	-	*	-
en_3772.txt	0	24	,	,	*	-	-	-	-	*	-
en_3772.txt	0	25	cognition	NN	(NP*)	-	-	-	-	*	-
en_3772.txt	0	26	,	,	*	-	-	-	-	*	-
en_3772.txt	0	27	and	CC	*	-	-	-	-	*	-
en_3772.txt	0	28	emotion	NN	(NP*)))))))))	-	-	-	-	*	-
en_3772.txt	0	29	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	By	IN	(TOP(S(PP*	-	-	-	-	*	-
en_3772.txt	0	1	blocking	VBG	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	2	glutamate	NN	(NP*)	-	-	-	-	*	-
en_3772.txt	0	3	from	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	4	binding	VBG	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	5	to	TO	(PP*	-	-	-	-	*	-
en_3772.txt	0	6	the	DT	(NP*	-	-	-	-	*	-
en_3772.txt	0	7	NMDA	NNP	*	-	-	-	-	*	-
en_3772.txt	0	8	receptor	NN	*))))))))	-	-	-	-	*	-
en_3772.txt	0	9	,	,	*	-	-	-	-	*	-
en_3772.txt	0	10	ketamine	NN	(NP*)	-	-	-	-	*	-
en_3772.txt	0	11	leads	VBZ	(VP(VP*	-	-	-	-	*	-
en_3772.txt	0	12	to	TO	(PP*	-	-	-	-	*	-
en_3772.txt	0	13	an	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	14	augmented	JJ	*	-	-	-	-	*	-
en_3772.txt	0	15	glutamate	NN	*	-	-	-	-	*	-
en_3772.txt	0	16	release	NN	*)	-	-	-	-	*	-
en_3772.txt	0	17	,	,	*	-	-	-	-	*	-
en_3772.txt	0	18	which	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_3772.txt	0	19	activates	VBZ	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	20	other	JJ	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	21	types	NNS	*)	-	-	-	-	*	-
en_3772.txt	0	22	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	23	glutamate	JJ	(NP*	-	-	-	-	*	-
en_3772.txt	0	24	receptors	NNS	*)))))))))	-	-	-	-	*	-
en_3772.txt	0	25	and	CC	*	-	-	-	-	*	-
en_3772.txt	0	26	enhances	VBZ	(VP*	-	-	-	-	*	-
en_3772.txt	0	27	the	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	28	function	NN	*	-	-	-	-	*	-
en_3772.txt	0	29	and	CC	*	-	-	-	-	*	-
en_3772.txt	0	30	density	NN	*)	-	-	-	-	*	-
en_3772.txt	0	31	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	32	synapses	NNS	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	33	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_3772.txt	0	34	the	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	35	junctions	NNS	*)	-	-	-	-	*	-
en_3772.txt	0	36	between	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	37	neurons	NNS	(NP*)))	-	-	-	-	*	-
en_3772.txt	0	38	-RRB-	-RRB-	*))))	-	-	-	-	*	-
en_3772.txt	0	39	in	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	40	areas	NNS	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	41	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	42	the	DT	(NP*	-	-	-	-	*	-
en_3772.txt	0	43	brain	NN	*))	-	-	-	-	*	-
en_3772.txt	0	44	where	WRB	(SBAR(WHADVP*)	-	-	-	-	*	-
en_3772.txt	0	45	stress	NN	(S(NP*	-	-	-	-	*	-
en_3772.txt	0	46	or	CC	*	-	-	-	-	*	-
en_3772.txt	0	47	depression	NN	*)	-	-	-	-	*	-
en_3772.txt	0	48	has	VBZ	(VP*	-	-	-	-	*	-
en_3772.txt	0	49	caused	VBN	(VP*	-	-	-	-	*	-
en_3772.txt	0	50	cells	NNS	(NP*	-	-	-	-	*	-
en_3772.txt	0	51	to	TO	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	52	atrophy	VB	(VP*))))))))))))	-	-	-	-	*	-
en_3772.txt	0	53	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	Increased	VBN	(TOP(S(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	1	synaptic	JJ	*	-	-	-	-	*	-
en_3772.txt	0	2	plasticity	NN	*)	-	-	-	-	*	-
en_3772.txt	0	3	–	SYM	(X(X*)	-	-	-	-	*	-
en_3772.txt	0	4	the	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	5	ability	NN	*)	-	-	-	-	*	-
en_3772.txt	0	6	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	7	synapses	NNS	(NP*	-	-	-	-	*	-
en_3772.txt	0	8	to	TO	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	9	adjust	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	10	their	PRP$	(NP*	-	-	-	-	*	-
en_3772.txt	0	11	strength	NN	*))))))))	-	-	-	-	*	-
en_3772.txt	0	12	,	,	*	-	-	-	-	*	-
en_3772.txt	0	13	which	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_3772.txt	0	14	is	VBZ	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	15	essential	JJ	(ADJP*	-	-	-	-	*	-
en_3772.txt	0	16	to	TO	(PP*	-	-	-	-	*	-
en_3772.txt	0	17	healthy	JJ	(NP*	-	-	-	-	*	-
en_3772.txt	0	18	brain	NN	*	-	-	-	-	*	-
en_3772.txt	0	19	function	NN	*)))	-	-	-	-	*	-
en_3772.txt	0	20	–	SYM	(X*)))))	-	-	-	-	*	-
en_3772.txt	0	21	could	MD	(VP*	-	-	-	-	*	-
en_3772.txt	0	22	be	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	23	the	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	24	neurobiological	JJ	*	-	-	-	-	*	-
en_3772.txt	0	25	reason	NN	*)	-	-	-	-	*	-
en_3772.txt	0	26	for	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	27	the	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	28	apparent	JJ	*	-	-	-	-	*	-
en_3772.txt	0	29	therapeutic	JJ	*	-	-	-	-	*	-
en_3772.txt	0	30	effect	NN	*)	-	-	-	-	*	-
en_3772.txt	0	31	in	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	32	patients	NNS	(NP*)))))))	-	-	-	-	*	-
en_3772.txt	0	33	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	But	CC	(TOP(S(S*	-	-	-	-	*	-
en_3772.txt	0	1	,	,	*	-	-	-	-	*	-
en_3772.txt	0	2	though	IN	(SBAR*	-	-	-	-	*	-
en_3772.txt	0	3	ketamine	NNS	(S(NP(NP*	-	-	-	-	*	(5
en_3772.txt	0	4	'	POS	*)	-	-	-	-	*	-
en_3772.txt	0	5	s	JJ	*	-	-	-	-	*	-
en_3772.txt	0	6	promise	NN	*)	-	-	-	-	*	5)
en_3772.txt	0	7	has	VBZ	(VP*	-	-	-	-	*	-
en_3772.txt	0	8	stirred	VBD	(VP*	-	-	-	-	*	-
en_3772.txt	0	9	excitement	NN	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	10	among	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	11	clinicians	NNS	(NP*	-	-	-	-	*	-
en_3772.txt	0	12	and	CC	*	-	-	-	-	*	-
en_3772.txt	0	13	neuroscientists	NNS	*)))))))	-	-	-	-	*	-
en_3772.txt	0	14	,	,	*	-	-	-	-	*	-
en_3772.txt	0	15	it	PRP	(NP*)	-	-	-	-	*	(5)
en_3772.txt	0	16	has	VBZ	(VP*	-	-	-	-	*	-
en_3772.txt	0	17	also	RB	(ADVP*)	-	-	-	-	*	-
en_3772.txt	0	18	sparked	VBN	(VP*	-	-	-	-	*	-
en_3772.txt	0	19	controversy	NN	(NP*))))	-	-	-	-	*	-
en_3772.txt	0	20	,	,	*	-	-	-	-	*	-
en_3772.txt	0	21	owing	VBG	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	22	to	TO	(PP*	-	-	-	-	*	-
en_3772.txt	0	23	the	DT	(NP*	-	-	-	-	*	(2
en_3772.txt	0	24	drug	NN	*))))	-	-	-	-	*	2)
en_3772.txt	0	25	'	''	*	-	-	-	-	*	-
en_3772.txt	0	26	s	VBZ	(VP*	-	-	-	-	*	-
en_3772.txt	0	27	potentially	RB	(NP(ADJP*	-	-	-	-	*	-
en_3772.txt	0	28	harmful	JJ	*)	-	-	-	-	*	-
en_3772.txt	0	29	side	NN	*	-	-	-	-	*	-
en_3772.txt	0	30	effects	NNS	*))	-	-	-	-	*	-
en_3772.txt	0	31	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	Depending	VBG	(TOP(S(S(S(VP*	-	-	-	-	*	-
en_3772.txt	0	1	on	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	2	the	DT	(NP*	-	-	-	-	*	-
en_3772.txt	0	3	dose	NN	*))))	-	-	-	-	*	-
en_3772.txt	0	4	,	,	*	-	-	-	-	*	-
en_3772.txt	0	5	a	DT	(NP*	-	-	-	-	*	-
en_3772.txt	0	6	patient	NN	*)	-	-	-	-	*	-
en_3772.txt	0	7	may	MD	(VP*	-	-	-	-	*	-
en_3772.txt	0	8	experience	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	9	altered	JJ	(NP*	-	-	-	-	*	-
en_3772.txt	0	10	physical	JJ	(ADJP*	-	-	-	-	*	-
en_3772.txt	0	11	,	,	*	-	-	-	-	*	-
en_3772.txt	0	12	spatial	JJ	*	-	-	-	-	*	-
en_3772.txt	0	13	,	,	*	-	-	-	-	*	-
en_3772.txt	0	14	and	CC	*	-	-	-	-	*	-
en_3772.txt	0	15	temporal	JJ	*)	-	-	-	-	*	-
en_3772.txt	0	16	states	NNS	*))))	-	-	-	-	*	-
en_3772.txt	0	17	;	:	*	-	-	-	-	*	-
en_3772.txt	0	18	larger	JJR	(S(NP*	-	-	-	-	*	-
en_3772.txt	0	19	quantities	NNS	*)	-	-	-	-	*	-
en_3772.txt	0	20	may	MD	(VP*	-	-	-	-	*	-
en_3772.txt	0	21	induce	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	22	hallucinations	NNS	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	23	and	CC	*	-	-	-	-	*	-
en_3772.txt	0	24	dissolution	NN	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	25	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	26	the	DT	(NP*	-	-	-	-	*	(6
en_3772.txt	0	27	self	NN	*)))))))	-	-	-	-	*	6)
en_3772.txt	0	28	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	Intriguingly	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_3772.txt	0	1	,	,	*	-	-	-	-	*	-
en_3772.txt	0	2	ketamine	FW	*	-	-	-	-	*	-
en_3772.txt	0	3	'	''	*	-	-	-	-	*	-
en_3772.txt	0	4	s	VBZ	(VP*	-	-	-	-	*	-
en_3772.txt	0	5	psychoactive	JJ	(SBAR(S(NP*	-	-	-	-	*	(7
en_3772.txt	0	6	properties	NNS	*)	-	-	-	-	*	7)
en_3772.txt	0	7	may	MD	(VP*	-	-	-	-	*	-
en_3772.txt	0	8	be	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	9	responsible	JJ	(ADJP*	-	-	-	-	*	-
en_3772.txt	0	10	for	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	11	its	PRP$	(NP*	-	-	-	-	*	(7)
en_3772.txt	0	12	mood-enhancing	JJ	*	-	-	-	-	*	-
en_3772.txt	0	13	effect	NN	*))))))))	-	-	-	-	*	-
en_3772.txt	0	14	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	Psychedelic	JJ	(TOP(S(NP(NP(ADJP*	-	-	-	-	*	-
en_3772.txt	0	1	and	CC	*	-	-	-	-	*	-
en_3772.txt	0	2	psycholytic	JJ	*)	-	-	-	-	*	-
en_3772.txt	0	3	treatments	NNS	*)	-	-	-	-	*	-
en_3772.txt	0	4	–	SYM	(X(X*)	-	-	-	-	*	-
en_3772.txt	0	5	popular	JJ	(ADJP*	-	-	-	-	*	-
en_3772.txt	0	6	in	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	7	the	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	8	1960	NNS	*	-	-	-	-	*	-
en_3772.txt	0	9	'	POS	*)	-	-	-	-	*	-
en_3772.txt	0	10	s	NN	*	-	-	-	-	*	-
en_3772.txt	0	11	and	CC	*	-	-	-	-	*	-
en_3772.txt	0	12	1970	CD	*))))	-	-	-	-	*	-
en_3772.txt	0	13	'	''	*)	-	-	-	-	*	-
en_3772.txt	0	14	s	VBZ	(VP*	-	-	-	-	*	-
en_3772.txt	0	15	,	,	*	-	-	-	-	*	-
en_3772.txt	0	16	before	IN	(SBAR*	-	-	-	-	*	-
en_3772.txt	0	17	research	NN	(S(S(NP*)	-	-	-	-	*	-
en_3772.txt	0	18	was	VBD	(VP*	-	-	-	-	*	-
en_3772.txt	0	19	severely	RB	(VP(ADVP*)	-	-	-	-	*	-
en_3772.txt	0	20	restricted	VBN	*)))	-	-	-	-	*	-
en_3772.txt	0	21	and	CC	*	-	-	-	-	*	-
en_3772.txt	0	22	interest	NN	(S(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	23	in	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	24	the	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	25	clinical	JJ	*	-	-	-	-	*	-
en_3772.txt	0	26	use	NN	*)	-	-	-	-	*	-
en_3772.txt	0	27	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	28	psychedelics	NNS	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	29	faded	VBD	(VP*	-	-	-	-	*	-
en_3772.txt	0	30	–	SYM	(NP*)))))))	-	-	-	-	*	-
en_3772.txt	0	31	were	VBD	(VP*	-	-	-	-	*	-
en_3772.txt	0	32	based	VBN	(VP*	-	-	-	-	*	-
en_3772.txt	0	33	on	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	34	the	DT	(NP*	-	-	-	-	*	-
en_3772.txt	0	35	notion	NN	*	-	-	-	-	*	-
en_3772.txt	0	36	that	IN	(SBAR*	-	-	-	-	*	-
en_3772.txt	0	37	the	DT	(S(NP*	-	-	-	-	*	(8
en_3772.txt	0	38	drug-induced	JJ	*	-	-	-	-	*	-
en_3772.txt	0	39	psychological	JJ	*	-	-	-	-	*	-
en_3772.txt	0	40	experience	NN	*)	-	-	-	-	*	8)
en_3772.txt	0	41	was	VBD	(VP*	-	-	-	-	*	-
en_3772.txt	0	42	essential	JJ	(ADJP*	-	-	-	-	*	-
en_3772.txt	0	43	to	TO	(PP*	-	-	-	-	*	-
en_3772.txt	0	44	facilitating	VBG	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	45	the	DT	(NP*	-	-	-	-	*	(9
en_3772.txt	0	46	psychotherapeutic	NN	*	-	-	-	-	*	-
en_3772.txt	0	47	process	NN	*))))))))))))))))	-	-	-	-	*	9)
en_3772.txt	0	48	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	According	VBG	(TOP(S(PP*	-	-	-	-	*	-
en_3772.txt	0	1	to	TO	(PP*	-	-	-	-	*	-
en_3772.txt	0	2	this	DT	(NP*	-	-	-	-	*	-
en_3772.txt	0	3	view	NN	*)))	-	-	-	-	*	-
en_3772.txt	0	4	,	,	*	-	-	-	-	*	-
en_3772.txt	0	5	the	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	6	altered	JJ	*	-	-	-	-	*	-
en_3772.txt	0	7	state	NN	*)	-	-	-	-	*	-
en_3772.txt	0	8	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	9	consciousness	NN	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	10	produced	VBN	(VP*	-	-	-	-	*	-
en_3772.txt	0	11	by	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	12	ketamine	NN	(NP(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	13	–	SYM	(X(X*)	-	-	-	-	*	-
en_3772.txt	0	14	particularly	RB	(NP(ADVP*)	-	-	-	-	*	-
en_3772.txt	0	15	the	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	16	dissolution	NN	*)	-	-	-	-	*	-
en_3772.txt	0	17	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	18	the	DT	(NP(NP*	-	-	-	-	*	(6
en_3772.txt	0	19	self	NNS	*	-	-	-	-	*	-
en_3772.txt	0	20	'	POS	*)	-	-	-	-	*	6)
en_3772.txt	0	21	s	JJ	*	-	-	-	-	*	-
en_3772.txt	0	22	boundaries	NNS	*)))	-	-	-	-	*	-
en_3772.txt	0	23	and	CC	*	-	-	-	-	*	-
en_3772.txt	0	24	the	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	25	experience	NN	*)	-	-	-	-	*	-
en_3772.txt	0	26	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	27	union	NN	(NP*))))))	-	-	-	-	*	-
en_3772.txt	0	28	with	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	29	the	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	30	world	NN	*)	-	-	-	-	*	-
en_3772.txt	0	31	–	SYM	(X*)))))))))	-	-	-	-	*	-
en_3772.txt	0	32	might	MD	(VP*	-	-	-	-	*	-
en_3772.txt	0	33	constitute	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	34	a	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	35	profound	JJ	(ADJP*	-	-	-	-	*	-
en_3772.txt	0	36	and	CC	*	-	-	-	-	*	-
en_3772.txt	0	37	meaningful	JJ	*)	-	-	-	-	*	-
en_3772.txt	0	38	experience	NN	*)	-	-	-	-	*	-
en_3772.txt	0	39	for	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	40	a	DT	(NP*	-	-	-	-	*	-
en_3772.txt	0	41	patient	NN	*)))))	-	-	-	-	*	-
en_3772.txt	0	42	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	Integrating	VBG	(TOP(S(S(VP*	-	-	-	-	*	-
en_3772.txt	0	1	this	DT	(NP*	-	-	-	-	*	(8
en_3772.txt	0	2	experience	NN	*)	-	-	-	-	*	8)
en_3772.txt	0	3	into	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	4	the	DT	(NP*	-	-	-	-	*	(9
en_3772.txt	0	5	psychotherapeutic	NN	*	-	-	-	-	*	-
en_3772.txt	0	6	process	NN	*))))	-	-	-	-	*	9)
en_3772.txt	0	7	might	MD	(VP*	-	-	-	-	*	-
en_3772.txt	0	8	facilitate	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	9	subsequent	JJ	(NP*	-	-	-	-	*	-
en_3772.txt	0	10	behavioral	JJ	*	-	-	-	-	*	-
en_3772.txt	0	11	changes	NNS	*)))	-	-	-	-	*	-
en_3772.txt	0	12	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	In	IN	(TOP(S(PP*	-	-	-	-	*	-
en_3772.txt	0	1	other	JJ	(NP*	-	-	-	-	*	-
en_3772.txt	0	2	words	NNS	*))	-	-	-	-	*	-
en_3772.txt	0	3	,	,	*	-	-	-	-	*	-
en_3772.txt	0	4	drugs	NNS	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	5	like	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	6	ketamine	NN	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	7	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_3772.txt	0	8	quickly	RB	(S(ADVP*)	-	-	-	-	*	-
en_3772.txt	0	9	increase	VBP	(VP*	-	-	-	-	*	-
en_3772.txt	0	10	neuroplasticity	NN	(NP*)))))))	-	-	-	-	*	-
en_3772.txt	0	11	might	MD	(VP*	-	-	-	-	*	-
en_3772.txt	0	12	be	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	13	particularly	RB	(VP(ADVP*	-	-	-	-	*	-
en_3772.txt	0	14	clinically	RB	*)	-	-	-	-	*	-
en_3772.txt	0	15	efficient	JJ	*	-	-	-	-	*	-
en_3772.txt	0	16	in	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	17	combination	NN	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	18	with	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	19	psychotherapeutic	JJ	(NP*	-	-	-	-	*	-
en_3772.txt	0	20	interventions	NNS	*)))))))	-	-	-	-	*	-
en_3772.txt	0	21	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	Unfortunately	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_3772.txt	0	1	,	,	*	-	-	-	-	*	-
en_3772.txt	0	2	research	NN	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	3	on	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	4	ketamine	NN	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	5	addicts	NNS	*)	-	-	-	-	*	-
en_3772.txt	0	6	and	CC	*	-	-	-	-	*	-
en_3772.txt	0	7	those	DT	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	8	who	WP	(SBAR(WHNP*)	-	-	-	-	*	-
en_3772.txt	0	9	take	VBP	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	10	it	PRP	(NP*)	-	-	-	-	*	(10)
en_3772.txt	0	11	in	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	12	large	JJ	(NP*	-	-	-	-	*	-
en_3772.txt	0	13	doses	NNS	*))	-	-	-	-	*	-
en_3772.txt	0	14	as	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	15	a	DT	(NP*	-	-	-	-	*	-
en_3772.txt	0	16	party	NN	*	-	-	-	-	*	-
en_3772.txt	0	17	drug	NN	*)))))))))	-	-	-	-	*	-
en_3772.txt	0	18	has	VBZ	(VP*	-	-	-	-	*	-
en_3772.txt	0	19	revealed	VBN	(VP*	-	-	-	-	*	-
en_3772.txt	0	20	that	IN	(SBAR*	-	-	-	-	*	-
en_3772.txt	0	21	its	PRP$	(S(NP*	-	-	-	-	*	(11|(10)
en_3772.txt	0	22	use	NN	*)	-	-	-	-	*	11)
en_3772.txt	0	23	may	MD	(VP*	-	-	-	-	*	-
en_3772.txt	0	24	lead	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	25	to	TO	(PP*	-	-	-	-	*	-
en_3772.txt	0	26	learning	VBG	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	27	and	CC	*	-	-	-	-	*	-
en_3772.txt	0	28	perception	NN	*	-	-	-	-	*	-
en_3772.txt	0	29	problems	NNS	*)	-	-	-	-	*	-
en_3772.txt	0	30	,	,	*	-	-	-	-	*	-
en_3772.txt	0	31	as	RB	(CONJP*	-	-	-	-	*	-
en_3772.txt	0	32	well	RB	*	-	-	-	-	*	-
en_3772.txt	0	33	as	IN	*)	-	-	-	-	*	-
en_3772.txt	0	34	memory	NN	(NP*	-	-	-	-	*	-
en_3772.txt	0	35	disorders	NNS	*)))))))))	-	-	-	-	*	-
en_3772.txt	0	36	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	Another	DT	(TOP(S(NP*	-	-	-	-	*	-
en_3772.txt	0	1	concern	NN	*)	-	-	-	-	*	-
en_3772.txt	0	2	is	VBZ	(VP*	-	-	-	-	*	-
en_3772.txt	0	3	that	IN	(SBAR*	-	-	-	-	*	-
en_3772.txt	0	4	ketamine	NNS	(S(NP(NP*	-	-	-	-	*	(12
en_3772.txt	0	5	'	POS	*)	-	-	-	-	*	12)
en_3772.txt	0	6	s	JJ	*	-	-	-	-	*	-
en_3772.txt	0	7	benefits	NNS	*)	-	-	-	-	*	-
en_3772.txt	0	8	may	MD	(VP*	-	-	-	-	*	-
en_3772.txt	0	9	be	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	10	relatively	RB	(ADJP*	-	-	-	-	*	-
en_3772.txt	0	11	fleeting	JJ	*))))))	-	-	-	-	*	-
en_3772.txt	0	12	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	As	IN	(TOP(S(PP*	-	-	-	-	*	-
en_3772.txt	0	1	a	DT	(NP*	-	-	-	-	*	-
en_3772.txt	0	2	result	NN	*))	-	-	-	-	*	-
en_3772.txt	0	3	,	,	*	-	-	-	-	*	-
en_3772.txt	0	4	ketamine	NN	(NP*)	-	-	-	-	*	(13)
en_3772.txt	0	5	may	MD	(VP*	-	-	-	-	*	-
en_3772.txt	0	6	never	RB	(ADVP*)	-	-	-	-	*	-
en_3772.txt	0	7	develop	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	8	into	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	9	an	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	10	accepted	JJ	*	-	-	-	-	*	-
en_3772.txt	0	11	treatment	NN	*)	-	-	-	-	*	-
en_3772.txt	0	12	for	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	13	depression	NN	(NP*))))	-	-	-	-	*	-
en_3772.txt	0	14	in	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	15	its	PRP$	(NP*	-	-	-	-	*	(13)
en_3772.txt	0	16	current	JJ	*	-	-	-	-	*	-
en_3772.txt	0	17	form	NN	*))))	-	-	-	-	*	-
en_3772.txt	0	18	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	In	IN	(TOP(S(PP*	-	-	-	-	*	-
en_3772.txt	0	1	fact	NN	(NP*))	-	-	-	-	*	-
en_3772.txt	0	2	,	,	*	-	-	-	-	*	-
en_3772.txt	0	3	ketamine	FW	*	-	-	-	-	*	-
en_3772.txt	0	4	'	''	*	-	-	-	-	*	-
en_3772.txt	0	5	s	VBZ	(VP*	-	-	-	-	*	-
en_3772.txt	0	6	future	NN	(NP*)	-	-	-	-	*	-
en_3772.txt	0	7	as	IN	(SBAR*	-	-	-	-	*	-
en_3772.txt	0	8	a	DT	(S(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	9	therapy	NN	*)	-	-	-	-	*	-
en_3772.txt	0	10	for	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	11	depression	NN	(NP*)))	-	-	-	-	*	(14)
en_3772.txt	0	12	would	MD	(VP*	-	-	-	-	*	-
en_3772.txt	0	13	be	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	14	uncertain	JJ	(ADJP*)	-	-	-	-	*	-
en_3772.txt	0	15	even	RB	(SBAR*	-	-	-	-	*	-
en_3772.txt	0	16	if	IN	*	-	-	-	-	*	-
en_3772.txt	0	17	its	PRP$	(S(NP*	-	-	-	-	*	(14)
en_3772.txt	0	18	efficacy	NN	*)	-	-	-	-	*	-
en_3772.txt	0	19	were	VBD	(VP*	-	-	-	-	*	-
en_3772.txt	0	20	more	RBR	(VP(ADVP*	-	-	-	-	*	-
en_3772.txt	0	21	strongly	RB	*)	-	-	-	-	*	-
en_3772.txt	0	22	established	VBN	*)))))))))	-	-	-	-	*	-
en_3772.txt	0	23	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	Because	IN	(TOP(S(S(SBAR*	-	-	-	-	*	-
en_3772.txt	0	1	ketamine	NN	(S(NP*)	-	-	-	-	*	-
en_3772.txt	0	2	has	VBZ	(VP*	-	-	-	-	*	-
en_3772.txt	0	3	been	VBN	(VP*	-	-	-	-	*	-
en_3772.txt	0	4	available	JJ	(ADJP*)	-	-	-	-	*	-
en_3772.txt	0	5	for	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	6	decades	NNS	(NP*))))))	-	-	-	-	*	-
en_3772.txt	0	7	,	,	*	-	-	-	-	*	-
en_3772.txt	0	8	there	EX	(NP*)	-	-	-	-	*	-
en_3772.txt	0	9	is	VBZ	(VP*	-	-	-	-	*	-
en_3772.txt	0	10	no	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	11	patent	NN	*)	-	-	-	-	*	-
en_3772.txt	0	12	for	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	13	it	PRP	(NP*)))))	-	-	-	-	*	(14)
en_3772.txt	0	14	,	,	*	-	-	-	-	*	-
en_3772.txt	0	15	so	IN	*	-	-	-	-	*	-
en_3772.txt	0	16	pharmaceutical	JJ	(S(NP*	-	-	-	-	*	-
en_3772.txt	0	17	companies	NNS	*)	-	-	-	-	*	-
en_3772.txt	0	18	have	VBP	(VP*	-	-	-	-	*	-
en_3772.txt	0	19	little	JJ	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	20	financial	JJ	*	-	-	-	-	*	-
en_3772.txt	0	21	incentive	NN	*)	-	-	-	-	*	-
en_3772.txt	0	22	to	TO	(SBAR(S(VP*	-	-	-	-	*	-
en_3772.txt	0	23	carry	VB	(VP(VP*	-	-	-	-	*	-
en_3772.txt	0	24	out	RP	(PRT*)	-	-	-	-	*	-
en_3772.txt	0	25	research	NN	(NP*)	-	-	-	-	*	-
en_3772.txt	0	26	on	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	27	the	DT	(NP*	-	-	-	-	*	(2
en_3772.txt	0	28	drug	NN	*)))	-	-	-	-	*	2)
en_3772.txt	0	29	and	CC	*	-	-	-	-	*	-
en_3772.txt	0	30	seek	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	31	approval	NN	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	32	for	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	33	its	PRP$	(NP*	-	-	-	-	*	(11|(2)
en_3772.txt	0	34	use	NN	*)))	-	-	-	-	*	11)
en_3772.txt	0	35	as	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	36	an	DT	(NP*	-	-	-	-	*	-
en_3772.txt	0	37	antidepressant	NN	*))))))))))	-	-	-	-	*	-
en_3772.txt	0	38	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	Nonetheless	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_3772.txt	0	1	,	,	*	-	-	-	-	*	-
en_3772.txt	0	2	research	NN	(NP(NP*)	-	-	-	-	*	(15
en_3772.txt	0	3	on	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	4	ketamine	NNS	(NP(NP*	-	-	-	-	*	(12
en_3772.txt	0	5	'	POS	*)	-	-	-	-	*	12)
en_3772.txt	0	6	s	JJ	*	-	-	-	-	*	-
en_3772.txt	0	7	chemistry	NN	*)))	-	-	-	-	*	15)
en_3772.txt	0	8	might	MD	(VP*	-	-	-	-	*	-
en_3772.txt	0	9	help	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	10	to	TO	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	11	identify	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	12	mechanisms	NNS	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	13	for	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	14	addressing	VBG	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	15	treatment-resistant	JJ	(NP*	-	-	-	-	*	-
en_3772.txt	0	16	depression	NN	*))))	-	-	-	-	*	-
en_3772.txt	0	17	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_3772.txt	0	18	are	VBP	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	19	based	VBN	(VP*	-	-	-	-	*	-
en_3772.txt	0	20	on	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	21	glutamate-driven	JJ	(NP*	-	-	-	-	*	-
en_3772.txt	0	22	neuroplasticity	NN	*))))))))))))	-	-	-	-	*	-
en_3772.txt	0	23	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	Indeed	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_3772.txt	0	1	,	,	*	-	-	-	-	*	-
en_3772.txt	0	2	pharmaceutical	JJ	(NP*	-	-	-	-	*	-
en_3772.txt	0	3	companies	NNS	*)	-	-	-	-	*	-
en_3772.txt	0	4	have	VBP	(VP*	-	-	-	-	*	-
en_3772.txt	0	5	already	RB	(ADVP*)	-	-	-	-	*	-
en_3772.txt	0	6	begun	VBN	(VP*	-	-	-	-	*	-
en_3772.txt	0	7	to	TO	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	8	investigate	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	9	other	JJ	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	10	NMDA-receptor	JJ	*	-	-	-	-	*	-
en_3772.txt	0	11	antagonists	NNS	*)	-	-	-	-	*	-
en_3772.txt	0	12	,	,	*	-	-	-	-	*	-
en_3772.txt	0	13	together	RB	(PP(ADVP*)	-	-	-	-	*	-
en_3772.txt	0	14	with	IN	*	-	-	-	-	*	-
en_3772.txt	0	15	drugs	NNS	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	16	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_3772.txt	0	17	act	VBP	(S(VP*	-	-	-	-	*	-
en_3772.txt	0	18	on	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	19	a	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	20	different	JJ	*	-	-	-	-	*	-
en_3772.txt	0	21	part	NN	*)	-	-	-	-	*	-
en_3772.txt	0	22	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	23	the	DT	(NP*	-	-	-	-	*	(4
en_3772.txt	0	24	glutamate	NN	*	-	-	-	-	*	-
en_3772.txt	0	25	system	NN	*)))))))))	-	-	-	-	*	4)
en_3772.txt	0	26	,	,	*)	-	-	-	-	*	-
en_3772.txt	0	27	as	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	28	possible	JJ	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	29	treatments	NNS	*)	-	-	-	-	*	-
en_3772.txt	0	30	for	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	31	depression	NN	(NP*)))))))))	-	-	-	-	*	-
en_3772.txt	0	32	.	.	*))	-	-	-	-	*	-

en_3772.txt	0	0	This	DT	(TOP(S(NP*	-	-	-	-	*	(15
en_3772.txt	0	1	research	NN	*)	-	-	-	-	*	15)
en_3772.txt	0	2	could	MD	(VP*	-	-	-	-	*	-
en_3772.txt	0	3	eventually	RB	(ADVP*)	-	-	-	-	*	-
en_3772.txt	0	4	lead	VB	(VP*	-	-	-	-	*	-
en_3772.txt	0	5	to	TO	(PP*	-	-	-	-	*	-
en_3772.txt	0	6	an	DT	(NP(NP*	-	-	-	-	*	-
en_3772.txt	0	7	entirely	RB	*	-	-	-	-	*	-
en_3772.txt	0	8	new	JJ	*	-	-	-	-	*	-
en_3772.txt	0	9	class	NN	*)	-	-	-	-	*	-
en_3772.txt	0	10	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	11	antidepressant	NN	(NP*	-	-	-	-	*	-
en_3772.txt	0	12	–	NN	*	-	-	-	-	*	-
en_3772.txt	0	13	and	CC	*	-	-	-	-	*	-
en_3772.txt	0	14	relief	NN	*))	-	-	-	-	*	-
en_3772.txt	0	15	for	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	16	millions	NNS	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	17	of	IN	(PP*	-	-	-	-	*	-
en_3772.txt	0	18	people	NNS	(NP(NP*)	-	-	-	-	*	-
en_3772.txt	0	19	worldwide	JJ	(ADJP*)))))))))	-	-	-	-	*	-
en_3772.txt	0	20	.	.	*))	-	-	-	-	*	-

#end document
